Feasibility study of single agent cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: Preliminary results

Japanese Journal of Clinical Oncology

Volumn 37, Issue 10, 2007, Pages 725-729

  Zenda, Sadamoto ^a   Onozawa, Yusuke ^b   Tahara, Makoto ^a   Kawashima, Mitsuhiko ^a   Shikama, Naoto ^c   Sasaki, Shigeru ^c   Boku, Narikazu ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoradiotherapy; Cisplatin; Head and neck; Racial difference; Squamous cell carcinoma

Indexed keywords

CISPLATIN;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLEEDING DISORDER; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DERMATITIS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INFUSION; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; JAPANESE; KIDNEY DYSFUNCTION; LEUKOPENIA; MALE; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; RACE DIFFERENCE; RADIATION DOSE; RECURRENT CANCER; SENSORY NEUROPATHY; SEX DIFFERENCE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANEMIA; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUCOSITIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION;

EID: 36248981469     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym106     Document Type: Article

References (18)

1. Stewart BW, Kleihues PE. World Cancer Report. Lyon: International Agency for Research on Cancer Press, 2003.
2. Kotwell C, Sako K, Zack MS, Rao U, Bakamjian V, Shedd DD. Metastatic pattern in squamous cell cancer of the head and neck. Am J Surg 1987;154:439-42.
3. Zbaeren P, Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. Arch Otalaryngol Head Neck Surg 1987;113:762-4.
4. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.
5. Adelstein DJ, Li Y, Adams GL, et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
6. Isobe K, Kawakami H, Uno T, et al. Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: Is intergroup study 0099 feasible in Japanese patients? Jpn J Clin Oncol 2003;33:497-500.
7. Forastiere AA, Goepfert H, Maor M, et al. Concurrent Chemotherapy and radiotherapy for Organ preservation in advanced Laryngeal Cancer. New Engl J Med 2003;349:2091-8.
8. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. New Engl J Med 2004;350:1937-44.
9. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. New Engl J Med 2004;350:1945-52.
10. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005;27:843-50.
11. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic in head and neck cancer. J Clin Oncol 2004;22:1743-52.
12. Union Internationale Centre le cancer. TNM classification of malignant tumors, 6th edn. New York: Wiley-Liss, 2002.
13. Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-I plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005;23:6957-65.
14. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-12.
15. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46.
16. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
17. Saikawa S. Report of head and neck cancer registry of Japan clinical statistics of registered patients, 2002. Jpn J Head Neck Cancer 2006;32(Suppl):1-14
18. Nishimura G, Tsukuda M, Horiuchi C, et al. Decrease of creatinine clearance rate with aging in patients with head and neck cancer Japan. Int J Clin Oncol 2007;12:120-4.